Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/15/2012US8178518 Mixture of androgen, macrocyclic ketone enhancer and thickener; glandular disorders
05/15/2012US8178517 6-methylvitamin D3 analogs and their uses
05/15/2012US8178516 Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites
05/15/2012US8178515 β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof
05/15/2012US8178514 Inositol pyrophosphates, and methods of use thereof
05/15/2012US8178513 Heterocyclic aspartyl protease inhibitors
05/15/2012US8178512 Methods and compositions for treating diseases and disorders associated with siglec-8.
05/15/2012US8178511 Method of administering hyaluronan formulation for the amelioration of osteopenia
05/15/2012US8178510 Preparation of thioarabinofuranosyl compounds and use thereof
05/15/2012US8178509 Method to treat sickle cell disease
05/15/2012US8178507 Method for the modulation of function of transcription factors
05/15/2012US8178506 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
05/15/2012US8178502 Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds
05/15/2012US8178501 Antibiotic combinations for providing total solution to the treatment of infections
05/15/2012US8178500 Pesticidal compositions
05/15/2012US8178499 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
05/15/2012US8178498 Medicament and method of treating an organism with medicaments
05/15/2012US8178348 For preventing gene transcription/expression; for inducing nuclease stability, hybridization to complementary RNA sequences, permeability to oligonucleotides into cells, RNase cleavage, and blocking ribosome translocation
05/15/2012US8178131 Pyrrolopyridines as kinase inhibitors
05/15/2012US8178128 Nanoparticles containing polymeric nucleic acid homologs
05/15/2012US8178124 Drug carrier and drug carrier kit for inhibiting fibrosis
05/15/2012US8178122 Use of nanomaterials based on titanium dioxide and zirconium diozide as coatings for osteointegrated biomedical prostheses, and osteointegrated biomedical prostheses prepared therewith
05/15/2012US8178121 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
05/15/2012US8178117 Liquid water based agrochemical formulations
05/15/2012US8178116 Methods and compositions for treating ectoparasite infestation
05/15/2012US8178115 Method and composition for the treatment of scars
05/15/2012US8178113 Cosmetic composition and methods of use
05/15/2012US8178099 administering locally a therapeutic amount of a Sost/Wise antagonist in conjunction with an osteoconductive biocompatible calcium salt scaffold; medical orthopedic or periodontal device; prevents kidney damage
05/15/2012US8178088 Antiprotozoal composition
05/15/2012US8178087 Process of production of bacteriophage compositions and methods in phage therapy field
05/15/2012US8178083 Treatment of optic neuritis
05/15/2012US8178082 Methods for up-regulating PAP1 in animals suffering from pancreatic disorders
05/15/2012US8178079 Ethylene copolymers, compositions containing said copolymers and treatment method
05/15/2012CA2717605C Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
05/15/2012CA2694480C Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
05/15/2012CA2678683C Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
05/15/2012CA2677690C Treatment of comorbid premature ejaculation and erectile dysfunction
05/15/2012CA2670703C Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
05/15/2012CA2650297C Hydroxymatairesinol in cancer prevention
05/15/2012CA2647360C Methods and compositions for deterring abuse of orally administered pharmaceutical products
05/15/2012CA2645558C Regulation of phospholipase d activity
05/15/2012CA2643005C Imidazole-5-carboxylic acid derivatives,the preparation method therefor and the uses thereof
05/15/2012CA2624810C Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
05/15/2012CA2614775C Compositions from buckwheat for management of diabetes
05/15/2012CA2597632C Substituted sulfoxide compounds, methods for preparing the same and use thereof
05/15/2012CA2581843C Thermodynamically stable form of bay 43-9006 tosylate
05/15/2012CA2576065C Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
05/15/2012CA2572631C A crystalline variable hydrate of (s)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9h-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- hemi-succinate salt
05/15/2012CA2558941C Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
05/15/2012CA2558782C Association between agomelatine and a noradrenaline recapture inhibitor and the pharmaceutical compositions that contain it
05/15/2012CA2553328C Pyridinium and quinolinium derivatives
05/15/2012CA2547347C Diazaindole-dicarbonyl-piperazinyl antiviral agents
05/15/2012CA2546781C Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
05/15/2012CA2536281C Ophthalmic composition comprising a 15-keto-prostaglandin compound
05/15/2012CA2532355C Process for preparation of 4-aryl-nicotinamide derivatives
05/15/2012CA2532199C Parasiticidal composition comprising a salicylanilide anti-parasitic compound
05/15/2012CA2530374C Hsp90 family protein inhibitors
05/15/2012CA2526616C Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
05/15/2012CA2526361C Amide derivative
05/15/2012CA2524323C Aminocyclohexyl ether compounds and uses thereof
05/15/2012CA2523740C Lactate containing pharmaceutical composition and uses thereof
05/15/2012CA2518591C Use of pyridin-2-yl-methylamine derivatives to prepare a medicine for treating symptoms of chronic pain of neuropathic or psychogenic origin
05/15/2012CA2517893C Use as medications of cholest-4-en-3-one derivatives, pharmaceutical compounds containing them, new derivatives and their preparation process
05/15/2012CA2517435C Hydroxypropylated starch for the treatment or prevention of obesity or diabetes
05/15/2012CA2517361C Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
05/15/2012CA2516993C Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
05/15/2012CA2496329C Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
05/15/2012CA2491167C Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation
05/15/2012CA2487332C Quaternised ammonium cyclodextrin compounds for use as antimicrobial agents, preservatives and penetration enhancers
05/15/2012CA2478223C Combinations comprising epothilone derivatives and alkylating agents
05/15/2012CA2470863C Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
05/15/2012CA2470500C Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
05/15/2012CA2464471C Method of treating depression with delta receptor agonist compounds
05/15/2012CA2463569C Activator for peroxisome proliferator-activated receptor .delta.
05/15/2012CA2461227C Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
05/15/2012CA2448933C A retinoic acid metabolizing cytochrome p450
05/15/2012CA2430978C Vla-4 inhibitors
05/15/2012CA2430816C Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
05/15/2012CA2422059C Methods and products related to low molecular weight heparin
05/15/2012CA2402169C Formulation and method for treating neoplasms by inhalation
05/15/2012CA2378243C Methods for treating or preventing pain and anxiety
05/15/2012CA2367291C Amplification of cyp24 and uses thereof
05/15/2012CA2365536C Compositions and methods for improved delivery of hydrophobic therapeutic agents
05/15/2012CA2358400C Methods for treating conditions associated with the accumulation of excess extracellular matrix
05/15/2012CA2283642C Therapeutic compositions
05/15/2012CA2219931C Stabilized standards and calibrators
05/10/2012WO2012061833A1 Compositions and methods for treating myelofibrosis
05/10/2012WO2012061822A2 Materials and methods for mobilizing cells including cd34+, hematopoietic colony forming, and endothelial colony forming cells
05/10/2012WO2012061820A2 Materials and methods for treating radiation poisoning
05/10/2012WO2012061807A1 Methods for inhibiting insect infestations
05/10/2012WO2012061767A2 Defensin-like molecules as novel antimicrobial agents
05/10/2012WO2012061717A1 Modified nicotinic compounds and related methods
05/10/2012WO2012061708A1 Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors
05/10/2012WO2012061703A1 Compositions and methods relating to reduced mucoadhesion
05/10/2012WO2012061698A2 Compounds useful as modulators of trpm8
05/10/2012WO2012061696A1 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k- delta inhibitors
05/10/2012WO2012061683A2 Methods for treating cancer
05/10/2012WO2012061662A1 Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
05/10/2012WO2012061651A1 Articles incorporating absorbert polymer and ceragenin compound
05/10/2012WO2012061630A2 Composition and method for treating skin conditions
1 ... 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 ... 7860